CGC vs. USNA, CRON, MNMD, BTMD, ACB, CDXC, IMTX, AORT, TYRA, and BCYC
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include USANA Health Sciences (USNA), Cronos Group (CRON), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), Immatics (IMTX), Artivion (AORT), Tyra Biosciences (TYRA), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector.
Canopy Growth (NASDAQ:CGC) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends.
In the previous week, Canopy Growth had 4 more articles in the media than USANA Health Sciences. MarketBeat recorded 7 mentions for Canopy Growth and 3 mentions for USANA Health Sciences. Canopy Growth's average media sentiment score of 1.03 beat USANA Health Sciences' score of 1.03 indicating that Canopy Growth is being referred to more favorably in the media.
USANA Health Sciences received 375 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 60.68% of users gave USANA Health Sciences an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.
USANA Health Sciences has a net margin of 6.88% compared to Canopy Growth's net margin of -326.75%. USANA Health Sciences' return on equity of 12.80% beat Canopy Growth's return on equity.
3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 0.4% of Canopy Growth shares are owned by company insiders. Comparatively, 0.3% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
USANA Health Sciences has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
Canopy Growth has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Canopy Growth presently has a consensus target price of $4.87, suggesting a potential downside of 56.04%. USANA Health Sciences has a consensus target price of $46.00, suggesting a potential downside of 5.60%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, analysts plainly believe USANA Health Sciences is more favorable than Canopy Growth.
Summary
USANA Health Sciences beats Canopy Growth on 13 of the 18 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
